Platform Technologies

PDS Biotech aims to advance and expand its proprietary pipeline programs independently or in collaboration with renowned research institutions and pharmaceutical companies.

Key commercial partners:

merck nih

Strategic Research Collaborations with:

NCI Stacked COLOR nih nih niaid mayo

PDS Biotech is dedicated to maximizing the full potential of the Versamune® platform in oncology and the Infectimune™ platform in infectious diseases.

Versamune® is a proprietary T-cell activating platform technology which induces a strong immune response in combination with tailored antigens to more effectively fight disease.

Infectimune™ is a proprietary T-cell immune activating platform technology designed to train the immune system to better protect against disease.

We are open to strategic partnerships which reflect the value-creating potential of Versamune® and Infectimune™ to provide performance-related downstream revenues, while preserving future growth opportunities for PDS Biotech.

Please contact our This email address is being protected from spambots. You need JavaScript enabled to view it.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up